Company intelligence / Profile preview

AT-Gruppe

Ownership: Private
Development stage: Other

Overview

AT-Gruppe appears to be a private German holding or investment entity rather than an operating life sciences, biotech, pharma, or healthcare company. Publicly available evidence is sparse, but it is referenced in corporate disclosures alongside other investment and holding vehicles associated with Helmut Jeggle. There is no clear evidence that AT-Gruppe itself develops therapeutics, operates a healthcare services business, or maintains a drug pipeline. It may have exposure to healthcare through investments, but the entity itself does not appear to be a dedicated life sciences operating company.

Industry: Investors

Beyond the preview

Go deeper on AT-Gruppe.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AT-Gruppe.

Explore the full profile